The total number of records retrieved from this search are 133. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_323	Virus nameCanine parvovirus	Virus strainCPV2.NS1	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationCPV genome expressing non-structural protein (NS1)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNCCS (National Centre for Cell Science, Pune, India)	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell linedensity of E+4 to E+5 cells/well in 120 microlitres of culture medium	In-vitro toxicityNA	AssayLDH assay	In-vitro virus concentrationNA	In-vitro result9% cancer cell death at 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis is induced via mitochondrial depolarization, release of cytochrome-c and activation of caspase 9	Immunogenic effectNA	Clinical trialNA	PMID26555166
IDOV_324	Virus nameCanine parvovirus	Virus strainCPV2.NS1	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationCPV genome expressing non-structural protein (NS1)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNCCS (National Centre for Cell Science, Pune, India)	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell linedensity of E+4 to E+5 cells/well in 120 microlitres of culture medium	In-vitro toxicityNA	AssayLDH assay	In-vitro virus concentrationNA	In-vitro result18% cancer cell death at 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis is induced via mitochondrial depolarization, release of cytochrome-c and activation of caspase 9	Immunogenic effectNA	Clinical trialNA	PMID26555166
IDOV_607	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell	Cell lineHeLa	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result85% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_610	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell	Cell lineHeLa	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result37% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_613	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell	Cell lineHeLa	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result8% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_616	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell	Cell lineHeLa	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result5% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_1106	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineCervical cancer cell line	Cell lineHeLaS3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayFluoroscent mesure at 450nm	In-vitro virus concentration0.01MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of delivery	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trialNA	PMID15958641
IDOV_1107	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineCervical cancer cell line	Cell lineHeLaS3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayFluoroscent mesure at 450nm	In-vitro virus concentration0.1MOI	In-vitro result35% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of delivery	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trialNA	PMID15958641
IDOV_1108	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineCervical cancer cell line	Cell lineHeLaS3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayFluoroscent mesure at 450nm	In-vitro virus concentration1MOI	In-vitro result15% cell viablity	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of delivery	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trialNA	PMID15958641
IDOV_1121	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineCervical cancer cell line	Cell lineHeLaS3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayFluoroscent mesure at 450nm	In-vitro virus concentration0.01MOI	In-vitro result50% cell viablity	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of delivery	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trialNA	PMID15958641
IDOV_1122	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineCervical cancer cell line	Cell lineHeLaS3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayFluoroscent mesure at 450nm	In-vitro virus concentration0.1MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of delivery	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trialNA	PMID15958641
IDOV_1123	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineCervical cancer cell line	Cell lineHeLaS3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayFluoroscent mesure at 450nm	In-vitro virus concentration1MOI	In-vitro result25% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of delivery	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trialNA	PMID15958641
IDOV_3045	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3046	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3047	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3075	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result18% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3076	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result1% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3077	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result1% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3661	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix cancer cell line	Cell lineHeLa	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result75% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3662	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix cancer cell line	Cell lineHeLa	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result68% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3677	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix cancer cell line	Cell lineHeLa	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3678	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix cancer cell line	Cell lineHeLa	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3693	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix cancer cell line	Cell lineHeLa	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result75% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3694	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix cancer cell line	Cell lineHeLa	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3803	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result18% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3804	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result22% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3805	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result23% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3806	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result23% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3807	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result25% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3808	Virus nameNewcastle disease virus	Virus strainNDVstrain 860	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result26% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3809	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result42% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3810	Virus nameNewcastle disease virus	Virus strainNDVstrain 769	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result45% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3811	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result45% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3812	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result60% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3813	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result60% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3814	Virus nameNewcastle disease virus	Virus strainNDVstrain AD	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result62% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3815	Virus nameNewcastle disease virus	Virus strainNDVstrain 429	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result65% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3816	Virus nameNewcastle disease virus	Virus strainNDVstrain 27	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result65% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3817	Virus nameNewcastle disease virus	Virus strainNDVstrain 718	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result65% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3818	Virus nameNewcastle disease virus	Virus strainNDVstrain 49	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result68% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3819	Virus nameNewcastle disease virus	Virus strainNDVstrain 52	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result68% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3820	Virus nameNewcastle disease virus	Virus strainNDVstrain 329	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result75% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3821	Virus nameNewcastle disease virus	Virus strainNDVstrain 12	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result75% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3822	Virus nameNewcastle disease virus	Virus strainNDVstrain 53	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result79% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3823	Virus nameNewcastle disease virus	Virus strainNDVstrain 746	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result79% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3824	Virus nameNewcastle disease virus	Virus strainNDVstrain 389	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result82% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3825	Virus nameNewcastle disease virus	Virus strainNDVstrain 339	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result85% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3826	Virus nameNewcastle disease virus	Virus strainNDVstrain 922	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result90% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3827	Virus nameNewcastle disease virus	Virus strainNDVstrain 945	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result95% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3828	Virus nameNewcastle disease virus	Virus strainNDVstrain 753	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3829	Virus nameNewcastle disease virus	Virus strainNDVstrain 48	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3830	Virus nameNewcastle disease virus	Virus strainNDVstrain 465	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3908	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result42% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3909	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result23% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3910	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result22% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3911	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result67% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3912	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result64% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3913	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3914	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result29% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3915	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result24% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3916	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result24% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3917	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result25% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3918	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result21% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3919	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result22% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3920	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result32% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3921	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result24% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3922	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result21% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3923	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result56% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3924	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result51% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3925	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3926	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result51% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3927	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result52% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3928	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result47% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3929	Virus nameNewcastle disease virus	Virus strainNDVstrain 769	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result51% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3930	Virus nameNewcastle disease virus	Virus strainNDVstrain 769	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result47% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3931	Virus nameNewcastle disease virus	Virus strainNDVstrain 769	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result46% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3932	Virus nameNewcastle disease virus	Virus strainNDVstrain 860	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result28% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3933	Virus nameNewcastle disease virus	Virus strainNDVstrain 860	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result20% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3934	Virus nameNewcastle disease virus	Virus strainNDVstrain 860	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result25% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3935	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result19% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3936	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result17% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3937	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result17% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3938	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result61% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3939	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result61% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3940	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result41% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3995	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result42% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3996	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result24% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3997	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result22% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4007	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result70% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4008	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result65% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4009	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result60% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4019	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result30% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4020	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result25% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4021	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result24% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4031	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result25% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4032	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result20% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4033	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result22% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4043	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result30% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4044	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result22% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4045	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result20% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4055	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4056	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result50% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4057	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result60% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4067	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result50% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4068	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result50% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4069	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of clinical and experimental lymphology, Russia	Origin of cell lineHuman epitheloid cervix carcinoma	Cell lineHeLa	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result45% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4304	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix adenocarcinoma	Cell lineHeLa	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result66 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4427	Virus nameVesicular stomatitis virus	Virus strainRdB	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration21:1 particle to pfu	In-vitro result60% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4435	Virus nameVesicular stomatitis virus	Virus strainRdB-1L-VSVG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration24:1 particle to pfu	In-vitro result20% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4885	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4886	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result98% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4887	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result88% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4888	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result88% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4889	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4890	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4891	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result10% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4892	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result100% cell killing aftwr 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4893	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4894	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4895	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result10% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4896	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineATCC	Origin of cell lineHuman cervix epithelial adenocarcinoma cell line	Cell lineHeLa	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result100% cell killing aftwr 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicitySlightly toxic to HeLa as measured by LDH assay	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_5066	Virus nameAvian orthoreovirus	Virus strainARV-PB1	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical cancer cell line	Cell lineHeLa	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28441762
IDOV_5196	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5197	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5198	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result80% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5199	Virus nameAdenovirus	Virus strainTRAD-shLuc	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for Luciferase gene knockout	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5200	Virus nameAdenovirus	Virus strainTRAD-shLuc	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for Luciferase gene knockout	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5201	Virus nameAdenovirus	Virus strainTRAD-shLuc	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for Luciferase gene knockout	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result80% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5202	Virus nameAdenovirus	Virus strainTRAD-shDICER	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for DICER	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5203	Virus nameAdenovirus	Virus strainTRAD-shDICER	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for DICER	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result60% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5204	Virus nameAdenovirus	Virus strainTRAD-shDICER	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for DICER	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman epithelia carcinoma cell line	Cell lineHeLa	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result10% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5621	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman cervical carcinoma cell line	Cell lineHeLa	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration4 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5841	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman cervical carcinoma cell line	Cell lineHeLa	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration4 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578